Kasten, Inc. (OTC PINK: KAST) announced today that it has completed a merger with Thru Pharma LLC dba DAKOTA Life Sciences. Upon review of Dakota during the phases of the JV setup, the Board of Directors and Members of Kasten and Dakota determined, it was in the best interests of both entities and their stockholders to consummate the merger of Kasten with and into Dakota with Kasten as the surviving entity.
Dakota Life Sciences is engaged in developing innovative health products utilizing Site Specific Penetration Technology SSPT™ technologies. These products include but are not limited to Thin Nail® (OTC First Aid Nail Antifungal), Symphony™ OTC First Aid Antibiotic, ThinNail® RX Topical Antifungal, Symphony ™ RX Topical Antibiotic, Reserve ™ Rx Line of Topical Antibiotics and an R&D pipeline of wound care and dermatology products, as well as other valuable life sciences technologies.
Dakota Life Sciences is a leading anti-infectives private pharmaceutical company with award-winning products designed to provide the highest efficacy for global patients at high risk of suffering from dangerous microbial and fungal infections.
“Dakota Life Sciences is the solution to take Kasten to the next level. They have a driven experienced management team and the product line already in place to enhance shareholder value,” stated Jose Delgado, CEO of Kasten, Inc.
“Dakota Life Sciences is very pleased to combine forces with Kasten,” said the President of Dakota Life Sciences, Steven Keough. “Our joint focus is to introduce a range of high efficacy affordable prescription and OTC pharmaceutical products that are unique to the market.”
SOURCE Kasten, Inc.